At Novartis, we use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. As a global company, we have a great responsibility and an even greater opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.

Front cover of the 2022 Novartis in Society Integrated Report, Van Lacour, prostate cancer patient living in Natchez, Louisiana, who received a Novartis radioligand therapy

Novartis in Society Integrated Report 2022

The Novartis in Society Integrated Report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create value for diverse stakeholders.

A female health worker talking a male patient through his medication steps and holding a bottle of pills in her hand.

Impact & Health Equity Update 2023

At our tenth annual ESG investor event, we shared updates on our two most material topics, Innovation and Access to Medicines, as well as how Novartis is preparing to meet upcoming reporting guidelines.

Building Trust with Society

Building trust with society is a key pillar of the Novartis corporate strategy and is critical to delivering on our purpose of reimagining medicine to improve and extend people’s lives. Our ESG efforts are integrated across the company and are key to driving long-term value for our stakeholders.

We believe a focus on our material ESG topics, coupled with our inspired, curious and unbossed culture will drive better performance. ESG topics form a core component of how the Novartis Executive Committee and the Board of Directors evaluate long-term performance of the company. We are committed to reporting transparently on these topics through our Annual Reporting Suite, which includes the Novartis in Society Integrated Report (PDF 8.7 MB), as well as our other Publications.

Doctor in Rwanda weighing a baby


We are committed to bringing more of our medicines to more people, no matter where they are.

We aim to conduct business responsibly wherever we operate with a focus on building a strong ethical foundation, respect for human rights, patient health and safety, diversity, equity and inclusion and the safety and well-being of our employees. We have clear commitments on many other social topics including the living wage, product quality and use of animals in research.

Thierry Diagana, Head of the Novartis Institute for Tropical Diseases (NITD)

Staying one step ahead of the malaria parasite

Thierry Diagana and his team are on a quest to discover new therapeutics for malaria. He believes malaria elimination is within our grasp, but emerging drug resistance could jeopardize the hard-fought progress.

Lutz Hegemann, M.D., Ph.D.

Doing the right thing is good business

Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.

Materiality Assessment and Impact Valuation

Our ESG priorities are defined by our materiality assessment, it helps us understand what matters to our stakeholders and how they perceive our impact.

Corporate Governance

Our corporate governance framework supports sustainable financial performance and long-term value creation and is aligned with our values and behaviors. In a rapidly changing business environment, we apply effective risk management to build resilience. We continue taking important steps to integrate our ESG agenda into the core of our business, enhancing executive accountability and measuring our performance against transparent targets. Members of the Executive Committee and other senior leaders have ESG targets in their annual objectives.

People relaxing in the Novartis Basel campus

Environmental, Social and Governance (ESG) Index

Novartis aims to report comprehensively and transparently about ESG topics. We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels.